BioMarin/BMRN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About BioMarin
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Ticker
BMRN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Rafael, United States
Employees
3,401
Website
www.biomarin.com
BioMarin Metrics
BasicAdvanced
$16B
Market cap
76.84
P/E ratio
$1.07
EPS
0.31
Beta
-
Dividend rate
Price and volume
Market cap
$16B
Beta
0.31
Financial strength
Current ratio
2.744
Quick ratio
1.548
Long term debt to equity
11.699
Total debt to equity
21.612
Interest coverage (TTM)
10.95%
Management effectiveness
Return on assets (TTM)
1.77%
Return on equity (TTM)
4.22%
Valuation
Price to earnings (TTM)
76.84
Price to revenue (TTM)
6.27
Price to book
3.07
Price to tangible book (TTM)
3.39
Price to free cash flow (TTM)
89.42
Growth
Revenue change (TTM)
13.74%
Earnings per share change (TTM)
188.87%
3-year revenue growth
10.25%
3-year earnings per share growth
-36.59%
What the Analysts think about BioMarin
Analyst Ratings
Majority rating from 28 analysts.
BioMarin Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$649M
0.40%
Net income
$89M
336.45%
Profit margin
13.65%
334.71%
BioMarin Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.29
$0.21
$0.11
$0.46
-
Expected
$0.23
$0.23
$0.23
$0.35
$0.34
Surprise
24.53%
-10.29%
-52.91%
33.33%
-
BioMarin News
AllArticlesVideos
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
PRNewsWire·2 weeks ago
BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress
PRNewsWire·4 weeks ago
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioMarin stock?
BioMarin (BMRN) has a market cap of $16B as of July 03, 2024.
What is the P/E ratio for BioMarin stock?
The price to earnings (P/E) ratio for BioMarin (BMRN) stock is 76.84 as of July 03, 2024.
Does BioMarin stock pay dividends?
No, BioMarin (BMRN) stock does not pay dividends to its shareholders as of July 03, 2024.
When is the next BioMarin dividend payment date?
BioMarin (BMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for BioMarin?
BioMarin (BMRN) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell BioMarin stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.